Research programme: histamine H4 receptor antagonists - Johnson and Johnson

Drug Profile

Research programme: histamine H4 receptor antagonists - Johnson and Johnson

Alternative Names: Histamine H4 antagonists - JNJPRD; JNJ-10191584; JNJ-7777120; VUF 6002

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Benzimidazoles; Indoles; Piperazines
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Allergic rhinitis; Atopic dermatitis; Pruritus; Respiratory tract disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pruritus in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top